Окситоцин и негативная симптоматика шизофрении

Oxytocin is a hormone that has been reported to reduce the severity of schizophrenia when administered intra-nasally. Rubin and colleagues from the University of Illinois at Chicago report that women with schizophrenia showed less severe symptoms on the Positive and Negative Syndrome Scale (PANSS) in the mid-luteal phase compared with the follicular phase. Higher oxytocin levels in both men and women were associated with more prosocial behaviors. This lends credence to the potential usefulness of oxytocin in schizophrenia, which also is being studied in autism. As a researcher, I also think this study points to the possibility that PANSS ratings in clinical trials of antipsychotics should control for the menstrual phase to avoid the confounding effects of a decline in severity of psychosis during the mid-luteal phase irrespective of drug treatment.

Oxytocin is a hormone that has been reported to reduce the severity of schizophrenia when administered intra-nasally. Rubin and colleagues from the University of Illinois at Chicago report that women with schizophrenia showed less severe symptoms on the Positive and Negative Syndrome Scale (PANSS) in the mid-luteal phase compared with the follicular phase. Higher oxytocin levels in both men and women were associated with more prosocial behaviors. This lends credence to the potential usefulness of oxytocin in schizophrenia, which also is being studied in autism. As a researcher, I also think this study points to the possibility that PANSS ratings in clinical trials of antipsychotics should control for the menstrual phase to avoid the confounding effects of a decline in severity of psychosis during the mid-luteal phase irrespective of drug treatment.

Peripheral oxytocin is associated with reduced symptom severity in schizophrenia